Search
CareDx Inc
CDNAAdd to Watchlist
19.970USD
-0.520-2.54%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
More Details of CareDx Inc Company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
CareDx Inc Info
Ticker SymbolCDNA
Company nameCareDx Inc
IPO dateJul 17, 2014
CEOHanna (John W)
Number of employees644
Security typeOrdinary Share
Fiscal year-endJul 17
Address8000 Marina Blvd
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone14152872300
Websitehttps://www.caredx.com/
Ticker SymbolCDNA
IPO dateJul 17, 2014
CEOHanna (John W)
Company Executives of CareDx Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
296.74K
-0.52%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
147.34K
+1.34%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
143.16K
-1.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
39.02K
-14.25%
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
37.05K
-4.14%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
28.79K
-25.66%
Mr. Suresh Gunasekaran
Mr. Suresh Gunasekaran
Director
Director
27.45K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
8.17K
-867.03%
Mr. George W. Bickerstaff, III
Mr. George W. Bickerstaff, III
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
296.74K
-0.52%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
147.34K
+1.34%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
143.16K
-1.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
39.02K
-14.25%
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
37.05K
-4.14%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
274.50M
72.27%
Digital and other revenue
56.93M
14.99%
Product revenue
48.38M
12.74%
By RegionUSD
Name
Revenue
Proportion
United States
359.94M
94.77%
Rest of the world
19.87M
5.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
274.50M
72.27%
Digital and other revenue
56.93M
14.99%
Product revenue
48.38M
12.74%
Shareholding Stats
Updated: Mon, May 11
Updated: Mon, May 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.79%
Baron Capital Management, Inc.
6.11%
State Street Investment Management (US)
5.30%
ARK Investment Management LLC
4.31%
Deerfield Management Company, L.P.
4.24%
Other
72.25%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.79%
Baron Capital Management, Inc.
6.11%
State Street Investment Management (US)
5.30%
ARK Investment Management LLC
4.31%
Deerfield Management Company, L.P.
4.24%
Other
72.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
43.81%
Investment Advisor
32.03%
Hedge Fund
20.15%
Research Firm
4.30%
Individual Investor
3.40%
Pension Fund
0.78%
Bank and Trust
0.42%
Insurance Company
0.03%
Family Office
0.02%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
469
52.46M
101.54%
-9.78M
2025Q4
443
52.64M
115.22%
+43.46K
2025Q3
457
52.61M
115.96%
-1.80M
2025Q2
454
53.72M
112.39%
-1.85M
2025Q1
443
55.89M
106.19%
-3.01M
2024Q4
439
52.97M
108.30%
+1.05M
2024Q3
434
51.58M
120.50%
-825.62K
2024Q2
407
52.51M
127.45%
-1.22M
2024Q1
435
53.86M
132.45%
-14.73M
2023Q4
448
52.78M
128.80%
-2.04M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.02M
7.85%
-97.03K
-2.36%
Dec 31, 2025
Baron Capital Management, Inc.
3.16M
6.16%
--
--
Dec 31, 2025
State Street Investment Management (US)
2.74M
5.35%
+171.30K
+6.67%
Dec 31, 2025
ARK Investment Management LLC
2.14M
4.17%
-34.22K
-1.58%
Dec 31, 2025
Deerfield Management Company, L.P.
2.19M
4.28%
--
--
Dec 31, 2025
Boston Partners
901.93K
1.76%
+870.57K
+2776.51%
Dec 31, 2025
Gagnon Securities LLC
1.77M
3.47%
+45.47K
+2.63%
Dec 31, 2025
Braidwell LP
1.59M
3.1%
-597.56K
-27.38%
Dec 31, 2025
Amova Asset Management Co., Ltd.
1.45M
2.82%
-293.45K
-16.86%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.89%
ROBO Global Healthcare Technology & Innovation ETF
1.93%
Global X Genomics & Biotechnology ETF
0.87%
Franklin Genomic Advancements ETF
0.72%
State Street SPDR S&P Biotech ETF
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
iShares Micro-Cap ETF
0.16%
Fidelity Enhanced Small Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Principal U.S. Small-Cap ETF
0.1%
View more
ARK Genomic Revolution ETF
Proportion2.89%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.93%
Global X Genomics & Biotechnology ETF
Proportion0.87%
Franklin Genomic Advancements ETF
Proportion0.72%
State Street SPDR S&P Biotech ETF
Proportion0.34%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.16%
Fidelity Enhanced Small Cap ETF
Proportion0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.11%
Principal U.S. Small-Cap ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
